The metabolic clearance of endogenous immunoreactive glucagon and exogenous glucagon in pancreatectomized and sham-operated pigs.

Hyperglucagonemia follows feeding in the pancreatectomized pig as it does in the pancreatectomized dog and man, but the cause of the rise in glucagon concentration is unknown. We report here the metabolic clearance and t½ of exogenous porcine glucagon infused into pigs and of endogenous immunoreactive glucagon (IRG) depressed by infusion of somatostatin. Somatostatin suppressed IRG levels to 70% of basal levels in pancreatectomized (P) pigs within 20 min of commencement of infusion and to 30% thereof in shamoperated (S) pigs within 50–60 min of commencement of infusion. In the S animals there was a breakthrough rebound within 6-8 h to levels approximately 175% of basal despite continued somatostatin infusion, while in the P animals a breakthrough to levels just above basal took place at 2 h in only two of seven animals. In the remaining five animals there was no rebound phenomenon. The half-life times determined from the slopes of disappearance were 42 ± 13 min in S animals and 55 ± 10 in P animals. In co...

[1]  J. Terblanche,et al.  The effect of feeding and starvation upon immunoreactive glucagon in the pancreatectomized pig. , 1978, Endocrinology.

[2]  A. Vinik,et al.  The effects of somatostatin on hormonal and metabolic responses in chronic pancreatitis. , 1977, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[3]  A. Vinik,et al.  Pancreatic Glucagon-Like Immunoreactivity in a Pancreatectomized Patient , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  P. Lefèbvre,et al.  Factors controlling gastric-glucagon release. , 1977, The Journal of clinical investigation.

[5]  S. Bloom,et al.  Pharmacokinetics of motilin in man. , 1977, Gastroenterology.

[6]  L. Orci,et al.  Physiology and pathophysiology of glucagon. , 1976, Physiological reviews.

[7]  P. Lefèbvre,et al.  Plasma glucagon after kidney exclusion: experiments in somatostatin-infused and in eviscerated dogs. , 1976, Metabolism: clinical and experimental.

[8]  M. Lorenzi,et al.  DIABETES WITHOUT GLUCAGON , 1976, The Lancet.

[9]  D. Le Roith,et al.  Somatostatin and serum gastrin in normal subjects and in patients with pernicious anaemia, chronic liver and renal disease. , 1975, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[10]  R. Unger,et al.  Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs. , 1975, Metabolism: clinical and experimental.

[11]  M. Ezequiel,et al.  Plasma Immunoreactive Insulin (IRI) and Immunoreactive Glucagon (IRG) After Evisceration with and Without a Functional Liver , 1975, Diabetes.

[12]  L. Orci,et al.  Glucagon: role in the hyperglycemia of diabetes mellitus. , 1975, Science.

[13]  M. Vranic,et al.  Increased “Glucagon Immunoreactivity” in Plasma of Totally Depancreatized Dogs , 1974, Diabetes.

[14]  C. J. Goodner,et al.  Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas , 1974, Science.

[15]  S. Solomon,et al.  Glucagon Clearance by the Isolated Perfused Rat Liver∗ , 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[16]  R. H. Williams,et al.  Studies on the metabolism of glucagon-I 131 in rats. , 1957, Endocrinology.